Additionally, FXR agonists also improved renal inflammation, fibrosis, lipid accumulation, and glucose metabolism disorders, which prevented the progression of chronic kidney disease (Evans et al., 2009; Wang et al., 2010; Zhou et al., 2016; Marquardt et al., 2017). Here, NR1H4 is linked to chronic kidney disease.